▲ +114.81% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $146.80, with a high forecast of $210.00 and a low forecast of $66.00. The average price target represents a 114.81% upside from the last price of $68.34.
The current consensus among 12 polled investment analysts is to buy stock in Axsome Therapeutics. This Buy consensus rating has held steady for over two years.
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.